**[INVITE]** 7/17 NYC Expert Lunch on Psychedelics - CMPS DFTX ATAI HELP GHRS

Research evidence excerpt

**[INVITE]** 7/17 NYC Expert Lunch on Psychedelics - CMPS DFTX ATAI HELP GHRS

USA | Biotechnology EquityJuneResearch30, 2026

**INVITE** 7/17 NYC Expert Lunch on

Psychedelics - CMPS DFTX ATAI HELP GHRS

On July 17 (Friday), we are hosting a 12pm ET lunch in NYC with a psychiatrist

to discuss: (1) Current use of JNJ Spravato in TRD depression (~$2B annual

runrate), (2) CMPS' COMP360 (psilocybin) pot'l 2027 adoption curve in TRD,

assuming YE:26/early 2027 approval, (3) Impressions of DFTX's DT120 (LSD)

(+) Phase III MDD data, (4) Other psychedelics in late-stage development (ATAI,

HELP, etc), (5) Overall drivers to ensure the successful launch of psychedelics.

.

Friday, July 17, 2026, at 12:00pm ET in New York City

Please contact your sales rep for info/registration.•

Hosted by Andrew Tsai, atsai@jefferies.com•

Relevant Tickers: DFTX, ATAI, CMPS, HELP, JNJ•

Discussion topics:

(1) Expected applicability of Spravato's 7,500+ site infrastructure for incoming psychedelic

treatments

Overview of Spravato (intranasal esketamine) and how it is delivered in practice, current•

bottlenecks, clinic economics (e.g., reimbursement, throughput, margins, etc), and barriers to

broader adoption

Intent to adopt psychedelics in MDD and TRD, and anticipated similarities and differences to•

the current interventional psychiatry model

Value of both short- and long-duration interventional psychedelic treatments, and the•

importance of real-world dosing frequency

Expected reimbursement and real-world staffing requirements for drug administration and•

monitoring for novel psychedelics

Implications of DEA scheduling and REMS program requirements•

Andrew Tsai * | Equity Analyst

(2) Major Depression (MDD) and TRD Depression: JNJ, CMPS, DFTX, HELP, ATAI, GHRS +1 (415) 229-1566 | atsai@jefferies.com